Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | CFO and Treasurer | July 02, 2018 | July 05, 2018 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Chief Financial Officer | February 02, 2026 | February 04, 2026 |
| Rein Therapeutics, Inc.RNTX · Entity 7071 | Director | July 23, 2025 | July 23, 2025 |
| Research Alliance Corp IVRACD · Entity 6687 | Director | July 10, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BELLICUM PHARMACEUTICALS, INC
Report date July 02, 2018 · Filed July 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.72 · Expires 2028-07-01 | Direct | 52,500 |
Reported balance
After 2018-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-02 · Grant · Acquired 52,500 · Balance 52,500 F1: 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
Fulcrum Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2036-02-01 | Direct | 170,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 170,000 · Balance 170,000 F1: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.
Rein Therapeutics, Inc.
Report date July 23, 2025 · Filed July 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2035-07-22 | Direct | 17,500 |
Reported balance
After 2025-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-23 · Grant · Acquired 17,500 · Balance 17,500 F1: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
Research Alliance Corp IV
Report date July 10, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-10 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Class B Ordinary Shares have no expiration date and will automatically convert into Class A Ordinary Shares of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis (subject to adjustment for sub-divisions, share dividends, reorganizations, recapitalizations and the like), or at any time prior thereto at the option of the holder on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights. |
Filing footnotes · ownership attribution and instrument terms
F1: Class B Ordinary Shares have no expiration date and will automatically convert into Class A Ordinary Shares of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis (subject to adjustment for sub-divisions, share dividends, reorganizations, recapitalizations and the like), or at any time prior thereto at the option of the holder on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 4, 2026 16:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001193125-26-037574 · ownership.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| July 23, 2025 Filed Jul 23, 2025 23:38 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0000950170-25-098043 · ownership.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-07-22 F1 · derivative.exercise_date: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 16:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 285,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-25-009818 · ownership.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: This option was granted on January 24, 2025 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2025, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| December 02, 2024 Filed Dec 6, 2024 21:32 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0000950170-24-134145 · ownership.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-12-01 F1 · derivative.exercise_date: This option was granted on December 2, 2024. The shares underlying the option are scheduled to vest in full on December 2, 2025. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:05 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000950170-24-099833 · ownership.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common Stock · 2,725 shares Expires 2034-08-19 F1 · derivative.exercise_date: This option was granted on August 20, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) August 20, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:05 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0000950170-24-009094 · ownership.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-25 F1 · derivative.exercise_date: This option was granted on January 26, 2024 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 16:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 61,822 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0000950170-24-005790 · ownership.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,822 Underlying: Common Stock · 61,822 shares Expires 2033-08-06 F1 · balance_after: This performance-based stock option was granted on August 7, 2023 and is subject to the achievement of certain pre-defined performance objectives pertaining to financial and investor relations goals within six months from the grant date, and subject to Mr. Musso continuing to be an "eligible participant" (as defined in Fulcrum Therapeutics, Inc.'s 2022 Inducement Stock Incentive Plan) through the vesting date. All performance objectives were met on January 17, 2024. Read SEC document |
| October 31, 2023 Filed Nov 3, 2023 00:53 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 5,450 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0000899243-23-020116 · doc4.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,450 Underlying: Common Stock · 5,450 shares Expires 2033-10-30 F1 · derivative.exercise_date: This option was granted on October 31, 2023. The shares underlying the option are scheduled to vest over 48 equal monthly installments from October 31, 2023, subject to continued service. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 16:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 432,800 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0000950170-23-040615 · ownership.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,800 Underlying: Common Stock · 432,800 shares Expires 2033-08-06 F1 · derivative.exercise_date: This option was granted on August 7, 2023 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of August 7, 2023. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:03 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001358403-18-000076 · wf-form4_153082102092716.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2028-07-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| May 25, 2018 Filed May 29, 2018 16:49 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | SaleCommon Stock | 6,206 | $7.97 | $49,466.16 |
DisclosureSEC source: 0001358403-18-000050 · wf-form4_152762693514280.xml · nonDerivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,548 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person on June 7, 2017. F2 · shares: Represents shares sold to satisfy tax liabilities and withholding obligations in connection with vesting of 14,706 shares of common stock from the Restricted Stock Awards granted to the Reporting Person on December 18, 2014. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.96 to $8.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth above. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 16:04 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionRestricted Stock Units · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001358403-18-000018 · wf-form4_151518624289946.xml · derivative · entry 3 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F3 · derivative.exercise_date: On January 3, 2017, the reporting person was granted 7,500 RSUs, of which 1,875 vested on January 3, 2018. The RSUs vest in four equal annual installments beginning January 3, 2018. F3 · derivative.expiration_date: On January 3, 2017, the reporting person was granted 7,500 RSUs, of which 1,875 vested on January 3, 2018. The RSUs vest in four equal annual installments beginning January 3, 2018. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 16:04 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Tax withholdingCommon Stock | 706 | $9.79 | $6,911.74 |
DisclosureSEC source: 0001358403-18-000018 · wf-form4_151518624289946.xml · nonDerivative · entry 2 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,754 F2 · kind: Represents the number of shares withheld by and surrendered to the Issuer on January 3, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 3, 2017 for 7,500 shares. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 16:04 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 1,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001358403-18-000018 · wf-form4_151518624289946.xml · nonDerivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:01 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001358403-18-000006 · wf-form4_151509970144349.xml · derivative · entry 2 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BLCM common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 2, 2019. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 2, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:01 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantEmployee Stock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001358403-18-000006 · wf-form4_151509970144349.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2028-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:05 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | SaleCommon Stock | 17,117 | $9.33 | $159,667.38 |
DisclosureSEC source: 0001358403-17-000171 · wf-form4_151319912870666.xml · nonDerivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,585 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person on June 7, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.13 to $9.52. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth above. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:06 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | SaleCommon Stock | 6,206 | $9.89 | $61,382.30 |
DisclosureSEC source: 0001358403-17-000169 · wf-form4_151199314620395.xml · nonDerivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,702 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person on June 7, 2017. F2 · shares: Represents shares sold to satisfy tax liabilities and withholding obligations in connection with vesting of 14,706 shares of common stock from the Restricted Stock Awards granted to the Reporting Person on December 17, 2014. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.85 to $9.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth above. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 16:09 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $11.70 | $0.00 |
DisclosureSEC source: 0001358403-17-000129 · wf-form4_149937178498083.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2027-07-02 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| May 25, 2017 Filed May 26, 2017 15:07 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | SaleCommon Stock | 6,311 | $12.24 | $77,253.58 |
DisclosureSEC source: 0001358403-17-000079 · wf-form4_149582561230485.xml · nonDerivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,908 F1 · kind: Represents shares sold to satisfy tax liabilities and withholding obligations in connection with vesting of 14,706 shares of common stock from the Restricted Stock Awards granted to the Reporting Person on December 17, 2014. F2 · balance_after: Includes 671 shares acquired under the Issuer's Employee Stock Purchase Plan on December 9, 2016. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:16 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001358403-17-000017 · wf-form4_148366177302043.xml · derivative · entry 2 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BLCM common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 3, 2018. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:16 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantEmployee Stock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001358403-17-000017 · wf-form4_148366177302043.xml · derivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2027-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| November 28, 2016 Filed Nov 29, 2016 16:05 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | SaleCommon Stock | 600 | $19.85 | $11,907.00 |
DisclosureSEC source: 0001358403-16-000294 · wf-form4_148045349793060.xml · nonDerivative · entry 3 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,548 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person on December 22, 2015. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.72 to $20.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 28, 2016 Filed Nov 29, 2016 16:05 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | SaleCommon Stock | 22,427 | $19.23 | $431,253.27 |
DisclosureSEC source: 0001358403-16-000294 · wf-form4_148045349793060.xml · nonDerivative · entry 2 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,148 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person on December 22, 2015. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.71 to $19.6826. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 25, 2016 Filed Nov 29, 2016 16:05 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | SaleCommon Stock | 6,273 | $20.48 | $128,480.45 |
DisclosureSEC source: 0001358403-16-000294 · wf-form4_148045349793060.xml · nonDerivative · entry 1 Musso Alan A · CIK 0001295830 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,575 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person on December 22, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.23 to $20.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 665 shares acquired under the Issuer's Employee Stock Purchase Plan, the "ESPP" on June 10, 2016; and 441 shares acquired under the ESPP on December 10, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.